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Summary
Background Determining the status of molecular pathways and key mutations in colorectal cancer is crucial for 
optimal therapeutic decision making. We therefore aimed to develop a novel deep learning pipeline to predict the 
status of key molecular pathways and mutations from whole-slide images of haematoxylin and eosin-stained colorectal 
cancer slides as an alternative to current tests.
Methods In this retrospective study, we used 502 diagnostic slides of primary colorectal tumours from 499 patients in 
The Cancer Genome Atlas colon and rectal cancer (TCGA-CRC-DX) cohort and developed a weakly supervised deep 
learning framework involving three separate convolutional neural network models. Whole-slide images were divided 
into equally sized tiles and model 1 (ResNet18) extracted tumour tiles from non-tumour tiles. These tumour tiles were 
inputted into model 2 (adapted ResNet34), trained by iterative draw and rank sampling to calculate a prediction score 
for each tile that represented the likelihood of a tile  belonging to the molecular labels of high mutation density (vs low 
mutation density), microsatellite instability (vs microsatellite stability), chromosomal instability (vs genomic stability), 
CpG island methylator phenotype (CIMP)-high (vs CIMP-low), BRAFmut (vs BRAFWT), TP53mut (vs TP53WT), and KRASWT 
(vs KRASmut). These scores were used to identify the top-ranked titles from each slide, and model 3 (HoVer-Net) 
segmented and classified the different types of cell nuclei in these tiles. We calculated the area under the convex hull 
of the receiver operating characteristic curve (AUROC) as a model performance measure and compared our results 
with those of previously published methods. 
Findings Our iterative draw and rank sampling method yielded mean AUROCs for the prediction of hypermutation 
(0·81 [SD 0·03] vs 0·71), microsatellite instability (0·86 [0·04] vs 0·74), chromosomal instability (0·83 [0·02] vs 0·73), 
BRAFmut (0·79 [0·01] vs 0·66), and TP53mut (0·73 [0·02] vs 0·64) in the TCGA-CRC-DX cohort that were higher than 
those from previously published methods, and an AUROC for KRASmut that was similar to previously reported 
methods (0·60 [SD 0·04] vs 0·60). Mean AUROC for predicting CIMP-high status was 0·79 (SD 0·05). We found 
high proportions of tumour-infiltrating lymphocytes and necrotic tumour cells to be associated with microsatellite 
instability, and high proportions of tumour-infiltrating lymphocytes and a low proportion of necrotic tumour cells to 
be associated with hypermutation. 
Interpretation After large-scale validation, our proposed algorithm for predicting clinically important mutations and 
molecular pathways, such as microsatellite instability, in colorectal cancer could be used to stratify patients for 
targeted therapies with potentially lower costs and quicker turnaround times than sequencing-based or immuno-
histochemistry-based approaches.
Funding The UK Medical Research Council.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license. 
Introduction 
Differing molecular pathways of colorectal cancer 
carcinogenesis can help to explain diversity in disease 
progression and tumour growth among patients.1 
Chromosomal instability is associated with lower rates of 
overall and progression-free survival in colorectal cancer,2 
whereas tumours with microsatellite instability or 
hypermutation are more likely to respond to immuno-
therapy.3–6 Further classifications consider different 
subgroups of CpG island methylator phenotypes 
(CIMPs) and microsatellite instability1,6,7 based on 
responses to adjuvant therapy and survival. Increasing 
numbers of studies have subtyped colorectal cancer on 
the basis of shared and distinct molecular characteristics 
and pathways1,8 and determined the association of these 
pathways with patient prognosis, overall survival, and 
response to specific treatments—particularly targeted 
therapy and immunotherapy.3,9,10 
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However, standard genetic (eg, PCR) and immuno-
histochemistry testing might incur time delays and 
additional costs,3,4 and molecular testing assays (eg, 
diagnostic biopsies) often require tissue, the availability 
of which can be limited.11 As such, visual examination of 
haematoxylin and eosin-stained tissue slides remains the 
gold standard for diagnosis of colorectal cancer. With the 
uptake and validation of digital pathology for routine 
diagnosis,12 multi-gigapixel whole-slide images can be 
generated and interrogated to yield information beyond a 
simple diagnosis. 
In histopathology, deep learning-based algorithms 
have been shown to predict clinically relevant molecular 
phenotypes,13 microsatellite instability,4,14,15 consensus 
mole cular subtypes,4,16 and outcomes17 in colorectal 
cancer. Indeed, Kather and colleagues4 developed a 
standard deep learning model using equal weighting of 
all tiles to stratify microsatellite instable and microsatellite 
stable colorectal cancer and achieved an area under the 
convex hull of the receiver operating characteristic curve 
(AUROC) of 0·77 (95% CI 0·62–0·87) on a test split of 
The Cancer Genome Atlas colon and rectal cancer 
(TCGA-CRC-DX) cohort. Kather and colleagues18 then 
extended this previously proposed computational 
pipeline4 to detect clinically actionable genetic alterations 
from haematoxylin and eosin-stained slides of multiple 
solid tumours. Echle and colleagues11 evaluated the use of 
deep learning models for the detection of microsatellite 
instability and mismatch repair deficiency on 
haematoxylin and eosin-stained slides from colorectal 
tumours, which showed a strong performance in intra-
cohort validation in three large international training sets 
and the TCGA-CRC-DX cohort (n=426). The performance 
of these models in intra-cohort and inter-cohort 
validation11 in the TCGA-CRC-DX cohort matched, but 
did not improve upon, the state-of-the-art performance of 
the previous microsatellite instability prediction method 
developed by Kather and colleagues.4
The labelling of a digitised whole-slide image as 
positive or negative for a specific genetic mutation or 
molecular pathway without detailed annotations at the 
cellular and regional levels would be considered weakly 
supervised learning in the language of machine learning. 
Weakly supervised learning of slide-level labels for 
whole-slide images and the detection of clinically 
actionable genetic alterations from the analysis of 
haematoxylin and eosin-stained whole-slide images have 
been shown to be possible with deep learning.4,11,18 
However, two fundamental questions remain 
unanswered. First, can deep learning be used to predict 
the status of molecular pathways and relevant genetic 
mutations from images of haematoxylin and eosin-
stained sections of colorectal cancer tumours with a 
high degree of accuracy? And, second, can these 
Research in context
Evidence before this study
We queried Google Scholar without language restrictions and 
with the search terms “(Predicting OR assessing) and (((msi OR 
dMMR) status) OR (tumor mutation burden OR TMB)) in 
(colorectal cancer) AND (Machine OR Deep) Learning OR 
(Artificial Intelligence OR AI)”, and analysed the top 50 scientific 
articles published between Jan 1, 2018, and Dec 20, 2020, to 
examine evidence before undertaking this study. Studies have 
shown that deep learning can predict the presence of 
microsatellite instability and genetic driver mutations directly 
from whole-slide images of haematoxylin and eosin-stained 
slides of colorectal cancer and other cancer types. However, 
previous methods using a standard deep learning model and 
equal weighting of all tiles for these predictions performed only 
modestly, especially in The Cancer Genome Atlas colon and 
rectal cancer (TCGA-CRC-DX) multicentre cohort. In addition, 
existing models have not assessed the cellular composition of 
histological regions that contribute to the final prediction. 
Added value of this study
Considering tissue heterogeneity, we hypothesised that all 
image tiles containing tissue contents in a whole-slide image 
are not equally predictive of the status of molecular pathways 
and key mutations. Therefore, in this retrospective study, we 
proposed a new, weakly supervised deep learning algorithm for 
whole-slide image classification based on non-annotated 
images and using only slide-level labels to predict the status of 
colorectal cancer pathways and mutations. We also cross-
validated the microsatellite instability prediction in a 
completely unseen cohort. The histological contents of strongly 
predictive tiles were systematically analysed in a data-driven 
manner. Our iterative draw and rank sampling method 
outperformed previously published methods in the prediction 
of hypermutation, microsatellite instability, chromosomal 
instability, and BRAF and TP53 mutation status in the TCGA-
CRC-DX cohort. 
Implications of all the available evidence
After large-scale validation in multicentre cohorts, our 
prediction algorithm could be used to stratify patients for 
targeted therapies, with potentially lower costs and quicker 
turnaround times than with current approaches. Indeed, the 
prediction of slide labels and their spatial mapping to the tissue 
microenvironment has the potential to improve diagnostic 
practice and personalised treatment for several different types 
of cancer. Automated analysis of the cellular composition of 
predictive histological features could improve our 
understanding of the downstream impact of these features and 
lead to new insights into representative and discriminative 
morphological features corresponding to molecular pathways 
and mutations for cancer. 
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predictions be mapped onto known or novel histological 
features? 
Several weakly supervised learning methods for com-
pu tational pathology have been proposed to maximise 
the use of available slide-level labels.19–21 For instance, 
Campanella and colleagues22 proposed a deep learning 
system based on multiple instance learning to 
discriminate between tumour and non-tumour whole-
slide images using high-level image labels only. However, 
the multiple instance learning method22 required tens of 
thousands of whole-slide images to effectively train the 
model. Although the authors chose only a few repre-
sentative top-ranked tiles from each slide, their method 
compared all tiles in the slide in each training epoch, 
which might be computationally expensive and requires 
a large amount of training data. Another weakly 
supervised method to classify whole-slide images 
proposed by Wang and colleagues23 requires pixel-level 
coarse annotations, which are labour-intensive and often 
unavailable, in addition to high-level image labels. Both 
these methods used an additional machine learning 
model to aggregate tile scores into a slide score. 
We aimed to develop a novel, weakly supervised, deep 
learning pipeline that could effectively predict the status 
of slide labels, and, in particular, key molecular pathways 
and specific mutations, from haematoxylin and eosin-
stained images of colorectal tumours, using only slide-
level labels (and not cell-level or regional-level 
annotations) for algorithm training. 
Methods
Study design 
In this retrospective study, we developed a novel, weakly 
supervised, deep learning framework involving three 
separate convolutional neural network models (figure 1). 
Because tumour tissue blocks taken during tumour 
sampling are large and almost always contain non-
tumour tissue, it is necessary to first identify the tumour 
areas. A fine-tuned convolutional neural network 
(ResNet18; model 1)24 was used as the tumour detection 
model (figure 1A) to identify tumour tiles in a given slide. 
These tumour tiles served as input to iterative draw and 
rank sampling (an adaptation of ResNet34; model 2), 
which learned the discriminative features of slide labels, 
molecular pathways, and mutations (ie, hypermutation, 
micro satellite instability, chromosomal instability, CIMP, 
BRAF, TP53, and KRAS  status) to calculate a digital 
score of the corresponding molecular status for each tile 
of the whole-slide image and the whole-slide image’s 
most predictive visual fields (figure 1B, C). The final 
convolutional neural network (HoVer-Net;25 model 3; 
figure 1D) used the top-ranked tiles (as predicted by 
iterative draw and rank sampling) to segment and classify 
different types of cell nuclei in each tile to analyse cellular 
composition. Then, the predicted digital scores of each 
pathway were investigated for their association with the 
status of colorectal cancer molecular pathways and key 
Figure 1: IDaRS prediction pipeline and histopathological feature discovery of colorectal cancer pathways
(A) Tissue segmentation and tile extraction were performed to obtain informative tiles. Model 1 (ResNet18) was 
trained to separate tumour from non-tumour tiles. These tiles served as input to iterative draw and rank sampling 
(an adaptation of ResNet34; model 2), which was trained on tumour tiles for label prediction. (B) A concept 
diagram of iterative draw and rank sampling illustrating the training strategy for the fast labelling of whole-slide 
images. The deep learning model was trained iteratively for classification with a random draw (di) of the same 
number of tiles from each whole-slide image and the k top-ranked tiles of the same slide drawn in the previous 
iteration. (C) The trained iterative draw and rank sampling model gave a prediction score to each tile in the whole-
slide image, which were used to obtain a slide score and identify the top-ranked tiles from each slide. (D) Model 3 
(HoVer-Net) inference was used to segment and classify different types of nuclei in top-ranked representative tiles 
in a cellular composition analysis of colorectal cancer pathways. Histological patterns of the molecular 
characteristics of colorectal cancers are shown as a spider plot based on the feature importance of different cellular 
composition profiles modelled via a support vector machine. H&E=haematoxylin and eosin. IDaRS=iterative draw 
and rank sampling. NEP1=neoplastic epithelial type 1. NEP2=neoplastic epithelial type 2. 





Di : IDaRS at training iteration i
di : draw subset of image tiles from a whole-slide image
Top Ki : top k tiles at iteration i












































4 www.thelancet.com/digital-health   Published online October 19, 2021   https://doi.org/10.1016/S2589-7500(21)00180-1
mutations. Both training and inference were used for the 
first two networks, whereas, for the third, only inferences 
were made by use of HoVer-Net, a state-of-the-art nuclear 
segmentation and classification model pre-trained on the 
publicly available PanNuke dataset.26
Data collection and preparation
We used 502 diagnostic slides of primary colorectal 
tumours (contributed by 36 different centres in the 
USA) from 499 patients in the TCGA-CRC-DX cohort, 
which has been used in previous studies (appendix 1 
pp 2–3).4,11,18 For external validation of the micro satellite 
status results, our iterative draw and rank sampling 
model was trained on the TCGA-CRC-DX cohort and 
tested on the Pathology Artificial Intelligence Platform 
(PAIP) challenge cohort, which contains 47 slides 
(12 micro satellite instable and 35 micro satellite stable) 
from three different centres in South Korea. The micro-
satellite status of each tumour was determined by PCR 
assays. The TCGA-CRC-DX dataset was deidentified and 
publicly available, and participant consent had previously 
been obtained by The Cancer Genome Atlas consortium. 
For the PAIP cohort, all necessary participant consent 
had been obtained and all study patients had been 
previously deidentified by Seoul National University 
Hospital (Seoul National University Hospital IRB 
number H-1808-035-964). Institutional permissions 
were received to use the PAIP dataset and no further 
ethics approval was required.
The iterative draw and rank sampling deep neural 
network model was trained for binary classification. The 
ground truth labels of the TCGA-CRC-DX cohort for 
hypermutation (high mutation density vs low mutation 
density), microsatellite instability (highly microsatellite 
instable vs microsatellite stable), chromosomal instability 
(chromosomal instability vs genomic stability), and 
CIMP (high [CIMP-high] vs low [CIMP-low] frequencies 
of DNA hypermethylation) were obtained from, and 
defined by, Liu and colleagues.1 For prediction of BRAF, 
TP53, and KRAS mutation, the binary classifications 
were either mutant or wild-type and were obtained from 
Kather and colleagues.18 All slides were pre-processed for 
tissue segmentation by use of Otsu thresholding.27 Then, 
the segmented tissue region in each whole-slide image 
was divided into equally sized tiles (256 μm by 256 μm). 
Further details about ground truth labels and data pre-
processing are provided in appendix 1 (pp 2–3). 
Deep learning framework
A deep neural network (ResNet18; model 1) was trained 
on a balanced dataset of tumour and non-tumour tiles, 
comprising 35 436 tiles from seven arbitrarily selected 
slides from the TCGA-CRC-DX cohort combined with 
two publicly available datasets (from Kather and 
colleagues4 and Shaban and colleagues28), to extract 
tumour tiles from the TCGA-CRC-DX cohort slides 
(appendix 1 p 3). 24 843 (70·1%) of the tiles were used for 
training, 5380 (15·2%) were used for validation, and the 
remaining 5213 (14·7%) comprised an unseen test set, 
which contained 2493 (47·8%) non-tumour tiles and 
2720 (52·2%) tumour tiles and was used to test model 
performance. We calculated accuracy and an F1 score to 
report the performance of the tumour segmentation 
model on the unseen test set.
The second neural network model was a fine-tuned 
version of ResNet34,24 pre-trained on ImageNet for the 
prediction of slide labels (ie, the status of molecular 
pathways and genetic mutations). Training was by Monte 
Carlo iterative draw and rank sampling and was done for 
30 iterations, with a batch size of 256. Trained model 2 
then calculated a prediction score for each tile in the 
whole-slide image, which can be considered the likelihood 
of a tile belonging to the positive class in our binary 
classification setting. These scores were used to identify 
the ten top-ranked tiles from each slide and to obtain a 
slide score by aggregating the scores of all tiles in a whole-
slide image and reporting the average probability-based 
aggregation. Further details about training and 
aggregation are provided in appendix 1 (pp 3–4). 
We used a final convolutional neural network 
(HoVer-Net;25 model 3) to segment and classify the 
different types of cell nuclei in the ten top-ranked tiles (as 
predicted by iterative draw and rank sampling) into five 
categories: neoplastic epithelial cells, non-neoplastic 
epithelial cells, inflammatory cells, mesenchymal cells, 
and necrotic cells. This step mimics the visual analysis of 
an expert pathologist who analyses nuclear composition 
in the tissue microenvironment subjectively under a 
microscope in a high-power field. The cell segmentation 
and classification results of HoVer-Net were visually 
examined by expert pathologists (AA and DS) for all cell 
types. We used the counts of individual cell types in each 
tile in a feature importance analysis to investigate 
potential associations between the cellular composition 
profile of top-ranked tiles for a given whole-slide image 
and molecular slide labels for hypermutation (high 
mutation density vs low mutation density), microsatellite 
instability (highly microsatellite instable vs microsatellite 
stable), chromosomal instability (chromosomal 
instability vs genomic stability), and CIMP (CIMP-high vs 
CIMP-low; appendix 1 pp 7–10). We calculated a tumour-
infiltrating lympho cyte abundance score: the abundance 
of tumour-infiltrating lympho cytes in the vicinity of the 
tumour regions.
Statistical analysis 
We used four-fold cross-validation in our prediction 
experiments to measure the mean iterative draw and 
rank sampling performance of the entire cohort. We 
used two folds for training, one fold as a validation set for 
keeping the best performing model, and one fold was 
kept aside as an unseen test set to measure model 
performance in a blinded way (appendix 1 p 5). We used 
the AUROC as a performance measure of the model 
See Online for appendix 1




The deidentified images for the 
PAIP challenge cohort can be 
obtained via appropriate data 
access requests at http://www.
wisepaip.org/paip
For more on ImageNet see 
https://image-net.org/
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predictions, and report the means and SDs of the 
AUROC values. 
We compared our results with those of a state-of-the-
art, automated microsatellite instability prediction model 
from a previous publication4 that used the same training-
to-test dataset split in the TCGA-CRC-DX cohort. We also 
compared our algorithm’s performance in a multi-fold 
cross-validation setting for microsatellite instability11 and 
other pathways and mutations (BRAF, TP53, and 
KRAS).18 Considering varying ratios of class imbalance 
(unequal samples in positive and negative classes) in the 
data, we also used average precision to calculate the area 
under the precision-recall curve (AUPRC). Both the 
AUROC and AUPRC were averaged for multiple runs 
and multiple folds of the experiments. 
For internal validation of our microsatellite instability 
prediction results, we matched the split of the TCGA-
CRC-DX cohort to that used by Kather and colleagues.4 
For external validation, our iterative draw and rank 
sampling model was trained on the TCGA-CRC-DX 
cohort and tested on the PAIP challenge cohort, which 
contained 47 slides from three different centres. Tumour 
tiles (n=58 097) were obtained from the PAIP cohort by 
use of the expert pathologist annotations of the tumour 
region provided in the PAIP challenge dataset.
Because of the importance of clinical stage in routine 
histopathology and colorectal cancer pathways and 
mutations, we also divided the entire TCGA-CRC-DX 
cohort by TNM stage (stage I, stage II, stage III, and 
stage IV) and computed the AUROC for each group 
separately.  
We overlaid local prediction heatmaps on top of whole-
slide images to further analyse the relationship of our 
molecular labels (hypermutation, microsatellite insta-
bility, chromosomal instability, and CIMP) with the 
spatial features of the tumour microenvironment. In our 
correlation analysis, we analysed the correlation between 
the iterative draw and rank sampling-based digital scores 
for hyper muta tion, microsatellite instability, chromo-
somal instability, CIMP, BRAF, and TP53 status for each 
slide of the TCGA-CRC-DX test set used previously by 
Kather and colleagues,4 obtained by applying separately 
trained models on the same training set. Feature 
importance in the cellular composition analysis is shown 
as the mean value for each pathway, and presented as box 
and whisker plots. Statistical significance (p values) for 
the difference between tumour-infiltrating lympho cyte 
abundance scores was assessed via paired t tests. 
Correlation coefficients (r) and p values for the correlation 
analysis were obtained by use of Pearson correlation. 
More details about our visualisation and correlation 
analyses can be found in appendix 1 (pp 10–11). We used 
scipy.stats library (version 1.5.2) in Python to calculate 
statistics. The p value cutoff of less than 0·05 was used 
for defining statistical significance and an r value cutoff of 
0·7 or –0·7 defined a strong correlation.
Samples (n) Published AUROC 






Four-fold cross-validation in the TCGA-CRC-DX cohort 
High vs low mutation density 430 67 363 0·7118 0·81 (0·03) 0·57 (0·09)
Microsatellite instability vs stability 428 62 366 0·74 (0·66–0·80)11 0·86 (0·04) 0·62 (0·10)
Chromosomal instability vs genomic stability 430 313 117 0·7318 0·83 (0·02) 0·92 (0·01)
CIMP-high vs CIMP-low 239 55 184 ·· 0·79 (0·05) 0·51 (0·05)
BRAFmut vs BRAFWT 502 59 443 0·6618 0·79 (0·01) 0·33 (0·05)
TP53mut vs TP53WT 502 294 208 0·6418 0·73 (0·02) 0·78 (0·04)
KRASmut vs KRASWT 502 208 294 0·6018 0·60 (0·04) 0·53 (0·04)
Train-test splits of TCGA-CRC-DX from Kather and colleagues4 
High vs low mutation density 359 66 293 ·· 0·88 (0·02) 0·66 (0·06)
Microsatellite instability vs stability 359 62 297 0·774 (0·62–0·87) 0·90 (0·01) 0·72 (0·02)
Chromosomal instability vs genomic stability 359 257 102 ·· 0·85 (0·02) 0·92 (0·02)
CIMP-high vs CIMP-low 203 51 152 ·· 0·84 (0·01) 0·61 (0·02)
Validation of prediction on TCGA-CRC-DX and PAIP datasets 
Microsatellite instability vs stability (internal) 359 62 297 0·774 (0·62–0·87) 0·90 0·72
Microsatellite instability vs stability (external) 47 12 35 ·· 0·98 0·95
Labels considered positive were high mutation density, microsatellite instability, chromosomal instability, CIMP-high, and mutant (BRAFmut, TP53mut, and KRASmut). Labels 
considered negative were low mutation density, microsatellite stability, genomic stability, CIMP-low, and wild-type (BRAFWT, TP53WT, and KRASWT). Alongside our analysis, we 
list published results from previous studies11,18 of three-fold cross-validation mean AUROCs and a train-to-test split4 AUROC in the TCGA-CRC-DX cohort. AUPRC=area under 
the precision-recall curve. AUROC=area under the convex hull of the receiver operating characteristic curve. CIMP=CpG island methylator phenotype. IDaRS=iterative draw 
and rank sampling. PAIP=Pathology Artificial Intelligence Platform. TCGA-CRC-DX=The Cancer Genome Atlas colon and rectal cancer. 
Table: Performance of the iterative draw and rank sampling method for prediction of hypermutation, microsatellite instability, chromosomal instability, 
and mutation status from haematoxylin and eosin-stained slides of colorectal cancer
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Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. 
Results
Model 1 achieved an accuracy and F1 score of 99% for the 
test tiles. This model was then used to identify tumour 
tiles (a total of 448 595 tiles) in the entire TCGA-CRC-DX 
cohort (appendix 1 p 3).
For the prediction of hypermutation status, 67 slides 
labelled high mutation density and 363 labelled low 
mutation density were considered for binary classi-
fication, with our iterative draw and rank sampling 
method yielding a mean cross-validation AUROC of 
0·81 (SD 0·03), compared with a previously published 
AUROC of 0·71 (table; figure 2).18 Among 62 slides 
labelled positive for high microsatellite instability and 
366 labelled microsatellite instability low or 
microsatellite stable, our iterative draw and rank 
sampling method outperformed the method used by 
Echle and colleagues,11 with a mean cross-validated 
AUROC of 0·86 (SD 0·04) versus 0·74 (95% CI 
0·66–0·80). Among 313 slides labelled as positive for 
chromosomal instability and 117 labelled as positive for 
genomic stability, our method outperformed the 
previously published method, with a mean AUROC of 
0·83 (SD 0·02) versus 0·73.18 Among 55 slides labelled 
CIMP-high and 184 labelled CIMP-low, our mean 
AUROC was 0·79 (SD 0·05). Our iterative draw and 
rank sampling method also outperformed previously 
published methods for the prediction of BRAF mutation 
status (0·79 [SD 0·01] vs 0·66) and TP53 mutation status 
(0·73 [0·02] vs 0·64), and showed similar performance 
to previously published methods for predicting KRAS 
mutation status (0·60 [0·04] vs 0·60).18
As Kather and colleagues4 used a subset of the 
current version of the TCGA-CRC-DX cohort, which 
contained 62 slides with microsatellite instability and 
297 with microsatellite stability, we used the same 
patient cohort and split the dataset into training and 
testing groups to compare our prediction of 
microsatellite instability with that by Kather and 
colleagues.4 Our iterative draw and rank sampling 
method outperformed the method used by Kather and 
colleagues,4 with a mean AUROC of 0·90 (SD 0·01) 
versus 0·77 (95% CI 0·62–0·87).
The highest AUPRC was obtained for predicting 
chromosomal instability, with relatively high values for 
predicting microsatellite instability, TP53 status, 
hypermutation, and CIMP (table). Generally, the higher 
the AUROC and the more balanced the dataset, the 
higher the AUPRC.
A breakdown of slide numbers from the TCGA-CRC-
DX cohort by molecular label and cancer stage can be 
found in appendix 1 (p 2), as can AUROC plots by 
molecular label and stage (p 6). Among the individual 
stage groups, hypermutation, chromosomal instability, 
and BRAF mutation status were predicted with the 
highest AUROC in patients with stage IV cancer, whereas 
microsatellite instability was predicted with the highest 
AUROC in patients with stage I or II disease (appendix 1 
pp 6–7). Our method was better at differentiating 
between CIMP-high and CIMP-low groups in patients 
with stage I, II, or III cancer than in patients with stage 
IV cancer (appendix 1 pp 6–7). We did not find any 
difference in accuracy for predicting TP53 status by 
cancer stage (appendix 1 pp 6–7). 
Model 3 (HoVer-Net) segmented and classified the cell 
nuclei in each top-ranked tile into five categories 
(appendix 1 pp 7–8). Non-neoplastic epithelial cells 
identified by model 3 differed from those identified by 
the model as neoplastic epithelial cells, but all of these 
were categorised as tumour cells by the experts (as only 
tumour tiles were used). Therefore, neoplastic epithelial 
Figure 2: Iterative draw and rank sampling-based prediction of colorectal cancer pathways in the 
TCGA-CRC-DX cohort  
AUROC plots of four-fold cross-validation for prediction of hypermutation (A), microsatellite instability (B), 
chromosomal instability (C), CpG island methylator phenotype (D), BRAF mutation status (E), and TP53 mutation 
status (F). The true positive rate represents sensitivity and the false positive rate represents 1–specificity. The blue 
shaded areas represent the SD. AUROC=area under the convex hull of the receiver operating characteristic curve. 
TCGA-CRC-DX=The Cancer Genome Atlas colon and rectal cancer.

















































Mean AUROC 0·81 (SD 0·03) Mean AUROC 0·86 (SD 0·04)
Mean AUROC 0·83 (SD 0·02) Mean AUROC 0·79 (SD 0·05)
Mean AUROC 0·79 (SD 0·01) Mean AUROC 0·73 (SD 0·02)
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cells identified by HoVer-Net are called neoplastic 
epithelial type 1 (NEP1) cells, and non-neoplastic 
epithelial cells identified by the model are called 
neoplastic epithelial type 2 (NEP2) cells.
A relatively high proportion of inflammatory and 
necrotic cells and a relatively low proportion of NEP1, 
NEP2, and mesenchymal cells were associated with 
microsatellite instability (figure 3). A relatively high 
proportion of inflammatory and NEP1 cells and a 
relatively low proportion of NEP2, mesenchymal, and 
necrotic cells were associated with hypermutation 
(figure 3). A relatively high proportion of inflammatory, 
necrotic, and NEP1 cells and a relatively low proportion 
of mesenchymal and NEP2 cells were associated with 
CIMP-high status (figure 3). A relatively high proportion 
of NEP2, mesenchymal, and NEP1 cells and a relatively 
low proportion of necrotic and inflammatory cells were 
associated with chromosomal instability (figure 3). Our 
feature importance analysis of cellular composition 
profiles by molecular label, in addition to our analysis of 
tumour-infiltrating lymphocyte abundance score by 
molecular label, can be found in appendix 1 (pp 8–10). 
Figure 3 suggests infiltration by inflammatory cells as a 
key discriminating histological feature in microsatellite 
instable and hypermutated tumors. Paired t tests found 
tumour-infiltrating lymphocyte abundance scores to be 
significantly associated with the microsatellite instability 
pathway (p=0·0024) and hypermutation (p=0·024), but 
not with the CIMP (p=0·090) and the chromosomal 
instability (p=0·16) pathways. This finding suggests that 
high proportions of tumour-infiltrating lymphocytes are 
strongly associated with microsatellite instable and 
hypermutated tumours.
As can be observed in our tile prediction heatmaps, 
similar tissue regions appear to be predictive of either a 
positive or negative status of the four colorectal cancer 
molecular labels or pathways (appendix 1 pp 10–11). 
However, tiles associated with the ground truth label 
differed in number between heatmaps (appendix 1 
pp 10–11).
Iterative draw and rank sampling-based digital scores 
for microsatellite instability and hypermutation showed 
a strong positive correlation, and the scores for 
microsatellite instability and CIMP showed a moderate 
positive correlation, wherein the microsatellite stability 
score showed the highest positive correlation with the 
CIMP-low score (appendix  1 pp 11–12). The digital scores 
of microsatellite instability and CIMP showed strong 
negative correlations with chromosomal instability 
(appendix 1 pp 11–12). Microsatellite instability had the 
strongest negative correlation with genomic stability, 
CIMP-low had the strongest negative correlation with 
chromosomal instability, and chromosomal instability 
had the strongest positive correlation with TP53 mutation 
status (appendix 1 pp 11–12). Microsatellite instability and 
CIMP scores were positively correlated with BRAF 
mutation (appendix 1 pp 11–12).
Discussion
In this retrospective study, we developed and validated a 
deep learning pipeline using the TCGA-CRC-DX cohort 
with similar experimental setups to those reported in 
previously published studies.4,11,18 We showed that using a 
novel training strategy in a standard deep learning model 
can improve the prediction of key molecular character-
istics and mutations in colorectal cancer tumours. Hyper-
mutation, micro satellite instability, chromosomal 
instability, BRAF mutation status, and TP53 mutation 
status were predictable from digitised images of routine 
haematoxylin and eosin-stained slides with a higher 
accuracy than previously published state-of-the-art 
computational algorithms. We also optimised our tumour 
segmentation algorithm, which ensured that non-tumour 
colon mucosa was not included in the analysis. 
We evaluated iterative draw and rank sampling for 
prediction of KRAS mutation status and BRAF mutation 
status, both of which could potentially be used for patient 
stratification for anti-epidermal growth factor receptor 
therapy. The US Food and Drug Administration have 
approved the use of immunotherapy for patients with 
colorectal cancers with high microsatellite instability, 
and so iterative draw and rank sampling could be used 
for patient selection using routine diagnostic histology 
slides. In the UK, the National Institute for Health and 
Care Excellence have also approved the use of encorafenib 
plus cetuximab for patients with previously treated, 
metastatic colorectal cancer positive for BRAF Val600Glu 
mutations. We hope that our algorithms might prove to 
be useful alternative tests for key mutations and pathways 
for patient stratification, potentially reducing turnaround 
time and saving resources.
Figure 3: Spider chart of differential cellular compositions as histological 
features of colorectal cancer pathways
Normalised weights between –1 and 1 show the size of significance of the 
corresponding histological feature. CIMP-high=CpG island methylator 
phenotype of high frequencies of DNA hypermethylation. NEP1=neoplastic 
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Our analysis of stage-wise prediction accuracy 
(AUROC) indicated that the prediction of hypermutation, 
molecular pathways (microsatellite instability, chromo-
somal instability, and CIMP), and key mutations (BRAF 
and TP53) might vary by cancer stage. For example, the 
accuracy of microsatellite instability prediction decreased 
slightly from stage I cancers to stage IV cancers. This 
finding indicates that tumour stage might affect deep 
learning-based discrimination of predictive features. 
Because we interrogated sections of primary tumours 
only, features of early-stage cancers with microsatellite 
instability could differ subtly from those of advanced 
cancers with microsatellite instability, perhaps due to the 
increased heterogeneity of advanced tumours. Similarly, 
hypermutation, chromosomal instability, and BRAF 
mutation status were predicted with the highest AUROC 
in patients with stage IV cancer. Exploring the predictive 
value of deep learning features of early-stage cancers 
might allow for more aggressive and targeted treatment 
to prevent disease progression.
Key challenges for prediction of microsatellite 
instability are the trade-off between sensitivity and 
specificity for clinical gold-standard testing (immuno-
histochemistry) and inconsistencies among different 
assays. Further improvements in the AUROC for 
microsatellite instability prediction and comparison with 
other molecular and genetic labels are possible if the 
specificity and sensitivity of the corresponding test used 
for acquiring the slide-level ground truth labels are 
improved and known beforehand, and the size of the 
dataset is increased. The ground truth microsatellite 
instability labels used in this study were based on 
molecular data in the TCGA-CRC-DX cohort and PCR 
assays in the PAIP cohort. The sensitivity (94%) and 
specificity (88%)29 of gold-standard, immunohisto-
chemistry-based testing should represent a minimum 
performance threshold that needs to be achieved by 
digital methods such as iterative draw and rank sampling 
for scoring micro satellite instability. Further large-scale 
validation of iterative draw and rank sampling on 
multiple international cohorts is necessary before it can 
be considered for clinical use. 
We did a cellular composition analysis to mine 
differential histological features for each of the colorectal 
cancer pathways, leveraging the ability of iterative draw 
and rank sampling to produce and overlay a prediction 
confidence heatmap on the original whole-slide images. 
Confidence heatmaps have shown that the tiles of both 
positive and negative labels with varying confidence are 
often predicted in an image, which could be linked to the 
difficulty of predicting microsatellite instability, especially 
when the immunogenic response of microsatellite 
stability is similar to the histomorphology of micro-
satellite instability.30 It could also indicate that a more 
sophisticated aggregation method than a simple average 
or majority voting might be needed to correctly classify 
some molecular characteristics. 
 Knowledge regarding stratification of colorectal cancer 
into multiple molecular pathways, and the morphological 
correlates and clinical significance of these pathways, is 
still evolving, and most findings so far are inconclusive. 
Gao and colleagues31 found that microsatellite instability 
was associated with low inflammatory cell infiltration, 
but not with tumour necrosis, in colorectal cancers; 
however, others9,32 found that tumour-infiltrating lympho-
cytes and an absence of tumour necrosis were strong 
predictors of microsatellite instability in colorectal 
cancers. In a study by Saller and colleagues,30 findings 
compatible with an immunogenic response were 
observed in the colorectal tumours of three patients, but 
different assays gave inconsistent interpretations of their 
microsatellite instability status. This contradiction can be 
attributed to the absence of an objective and systematic 
data-driven approach for anal ysis of the entire tissue 
slide for multicentre cohorts. In the existing literature, 
histological correlates of molecular characteristics (eg, 
microsatellite instability) are often examined only 
subjectively.6,7,9,31–34 We believe that our iterative draw and 
rank sampling-based analysis is a first step towards an 
objective, quantitative, and reproducible approach for 
analysing colorectal cancer pathways from routine 
histology slides and studying their corresponding 
histological correlates in a systematic and data-driven 
manner. 
A relatively high proportion of NEP2, mesenchymal, 
and NEP1 cells and a relatively low proportion of 
necrotic and inflammatory cells were associated with 
chromo somal instability. This finding could explain the 
potential association of chromosomal instability with 
less favourable outcomes.2,9 The strong association of 
CIMP-high with a high proportion of inflammatory 
cells and a low proportion of mesenchymal cells found 
in our cellular composition analysis might suggest the 
molecular characteristics of an active immune response, 
as reported previously.7 A relatively high proportion of 
inflammatory and necrotic cells and a relatively low 
proportion of NEP1, NEP2, and mesenchymal cells were 
associated with microsatellite instability. This finding 
could explain the favourable response of tumours with 
microsatellite instability to immunotherapy.35,36 Our 
differential cellular composition analysis suggests that 
the infiltration scores of lymphocytes and necrosis 
within the tumour can serve as digital biomarkers for 
further stratification and the analysis of each pathway 
and its clinical impact. Our findings of a strong 
correlation between microsatellite instability and 
hypermutation,1,3,37 a moderate correlation between 
microsatellite instability and CIMP,6,7 and a high 
infiltrate of inflammatory cells in microsatellite instable 
tumours9,32,34 are in line with existing literature. The 
cellular composition profiles of microsatellite instability, 
hypermutation, chromosomal instability, and CIMP 
groups potentially add new knowledge to the literature 
regarding the associations between molecular labels 
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and cell types, requiring large validation and further 
exploration with subsequent studies.
Our iterative draw and rank sampling algorithm uses 
Monte Carlo sampling to iteratively select training data 
from each whole-slide image, leading to a slightly 
different trained model for each run. Therefore, we ran 
each experiment three times with the same data splits 
and report averaged measures. The number of randomly 
drawn tiles, top-ranked tiles, and maximum training 
iterations used in the iterative draw and rank sampling 
training algorithm might not have been optimal 
(appendix 1 p 6). These values might need to be adjusted 
for a given problem. Data imbalance—having a different 
number of positive and negative samples in a binary 
classification dataset—is another common issue with 
medical datasets, which can affect classification 
performance. We therefore reported the AUPRC results 
in addition to the AUROC results. External validation 
was done on 47 whole-slide images from the PAIP dataset 
obtained from three different centres, which is a relatively 
small dataset. A pre-trained HoVer-Net model—a state-
of-the-art alogorithm—was used for nuclei segmentation 
and classification, which was followed by a review by 
expert pathologists (AA and DS). However, nuclear 
segmentation and classification from haematoxylin and 
eosin-stained images is known to be a challenging task; 
therefore, our classification of neoplastic and stromal 
cells for the TCGA-CRC-DX cohort might have been 
imperfect, affecting our interpretation of the importance 
of these cell types. Although the TCGA-CRC-DX cohort 
is a multicentre dataset and PAIP is an external cohort, 
further large-scale validation of these findings is required 
before implementation into diagnostic practice and 
patient management. 
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